Key points from article :
Decline of NAD leads to metabolic disturbances and sets the stage for various age-related diseases.
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), sold as dietary supplements, to restore NAD levels.
NMN and NR both have limitations.
A new study suggests that there could be a new game in town with the arrival of reduced nicotinamide mononucleotide (NMNH).
Potent NAD precursor molecule, according to the results seen in both mice and human cells.
NMNH is efficiently processed into NAD in cells.
Path to achieving this does not involve NRK or NAMPT, which other precursors require to become NAD.
Can also protect renal proximal tubular epithelial cells from hypoxia/reoxygenation‐induced injury.
NMNH treatment in mice is able to raise NAD levels in their blood but also in multiple tissues to a higher level than NMN.
Can be made available at a far lower price point than the precursors currently available.
